OBJECTIVES: We report our experience using ureteroscopic or percutaneous management of upper tract transitional cell carcinoma (TCC) in elective situations. METHODS: Between 1983 and 2004 we identified 83 patients who underwent endoscopic management of upper tract TCC in the setting of a normal contralateral kidney. We performed a retrospective chart review and conducted outcome analyses. RESULTS: Median age at diagnosis was 71 years (range, 37 to 90 years) and median tumor size was 0.8 cm (range, 0.2 to 3.0 cm). Grade 3 tumors were present in 8 patients (10%), whereas the remaining 75 (90%) patients were grade 1 or 2 or diagnosed as visual low grade. Tumor stage was Ta or visual Ta in 78 patients (94%). Median follow-up was 4.6 years (range, 0.4 to 17 years) during which 46 patients (55%) developed 76 upper tract recurrences and 37 patients (45%) developed a recurrence in the bladder. At last follow-up, 27 patients (33%) required a nephroureterectomy and 9 patients (11%) died from TCC. Patients with high-grade (risk ratio, 9.8; P = 0.001) and non-Ta stage tumors (risk ratio, 5.7; P = 0.003) were at significant risk of death from disease. Among 43 patients with a diagnosis based on visual inspection only, 9 (21%) developed grade 3 TCC during follow-up. CONCLUSIONS: Our results underscore the need for strict surveillance after endoscopic management of upper tract TCC. Recurrence is common and nearly one-third of patients in this cohort eventually required nephroureterectomy. Patients with a visual diagnosis, without adequate tissue for pathologic analysis, can experience recurrence of high-grade invasive TCC.
OBJECTIVES: We report our experience using ureteroscopic or percutaneous management of upper tract transitional cell carcinoma (TCC) in elective situations. METHODS: Between 1983 and 2004 we identified 83 patients who underwent endoscopic management of upper tract TCC in the setting of a normal contralateral kidney. We performed a retrospective chart review and conducted outcome analyses. RESULTS: Median age at diagnosis was 71 years (range, 37 to 90 years) and median tumor size was 0.8 cm (range, 0.2 to 3.0 cm). Grade 3 tumors were present in 8 patients (10%), whereas the remaining 75 (90%) patients were grade 1 or 2 or diagnosed as visual low grade. Tumor stage was Ta or visual Ta in 78 patients (94%). Median follow-up was 4.6 years (range, 0.4 to 17 years) during which 46 patients (55%) developed 76 upper tract recurrences and 37 patients (45%) developed a recurrence in the bladder. At last follow-up, 27 patients (33%) required a nephroureterectomy and 9 patients (11%) died from TCC. Patients with high-grade (risk ratio, 9.8; P = 0.001) and non-Ta stage tumors (risk ratio, 5.7; P = 0.003) were at significant risk of death from disease. Among 43 patients with a diagnosis based on visual inspection only, 9 (21%) developed grade 3 TCC during follow-up. CONCLUSIONS: Our results underscore the need for strict surveillance after endoscopic management of upper tract TCC. Recurrence is common and nearly one-third of patients in this cohort eventually required nephroureterectomy. Patients with a visual diagnosis, without adequate tissue for pathologic analysis, can experience recurrence of high-grade invasive TCC.
Authors: Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon Journal: Can Urol Assoc J Date: 2013 Sep-Oct Impact factor: 1.862
Authors: Michael Metcalfe; Gavin Wagenheim; Lianchun Xiao; John Papadopoulos; Neema Navai; John W Davis; Jose A Karam; Ashish M Kamat; Christopher G Wood; Colin P Dinney; Surena F Matin Journal: J Endourol Date: 2017-07-21 Impact factor: 2.942
Authors: Alexander Sankin; Amy L Tin; Roy Mano; Michael Chevinsky; Chris Jakubowski; John P Sfakianos; Eugene K Cha; Alyssa Yee; Fara M Friedman; Daniel D Sjoberg; Behfar Ehdaie; Jonathan Coleman Journal: Urology Date: 2016-05-26 Impact factor: 2.649
Authors: Michael J Amirian; Kushan Radadia; Hadley Narins; Kelly A Healy; Scott G Hubosky; Demetrius Bagley; Edouard J Trabulsi; Costas D Lallas Journal: J Endourol Date: 2014-07-16 Impact factor: 2.942